TOKYO, May 29 (Pulse News Wire) – Astellas Pharma Inc. (4503.T) announced today that Andreas Busch, an external director, resigned effective May 29, 2026.
As a result, the company decided to withdraw part of its agenda item for the upcoming 21st Ordinary General Meeting of Shareholders scheduled for June 19, 2026. Specifically, the proposal to elect seven directors (excluding audit committee members) was revised to select six directors instead. The changes reflect Mr. Busch's decision to step down as a candidate for an external director position. Consequently, the list of candidates for directors (excluding audit committee members) now includes eight individuals, excluding Mr.
Busch. The remaining candidates remain unchanged. Following the resignation, the board continues to meet legal requirements for the number of directors. Assuming approval of the revised proposals, the board would consist of ten members, including six independent outside directors. Astellas Pharma focuses on transforming scientific advancements into patient value across various therapeutic areas such as oncology, ophthalmology, urology, immunology, and women’s health.
The company actively develops innovative treatments through its research programs aimed at addressing unmet medical needs.
🟢 Confidence: High AI-translated content.